|Bid||1,669.40 x 0|
|Ask||1,670.40 x 0|
|Day's Range||1,645.40 - 1,671.60|
|52 Week Range||1,408.80 - 1,671.60|
|Beta (3Y Monthly)||0.84|
|PE Ratio (TTM)||21.28|
|Earnings Date||Jul 24, 2019|
|Forward Dividend & Yield||0.76 (4.68%)|
|1y Target Est||1,644.50|
Two Boston-based investment firms have joined the fray of firms raising new funds, collecting a combined $700 million according to financial disclosures made in the last week.
The company bought the drug when it acquired U.S. cancer specialist Tesaro for $5.1 billion in December and Zejula is already approved for certain ovarian cancer patients. For GSK, the success of Zejula would help it access a wider population group and give it an edge over rival PARP inhibitors such as AstraZeneca and Merck & Co's Lynparza and Clovis Oncology's Rubraca. "Zejula's potential to expand PARP use beyond BRCAm (BRCA mutation) patients, was a key justification for its Tesaro acquisition and this required a positive outcome for Zejula in the PRIMA study," Jefferies analysts said.
(Bloomberg) -- Machine-learning technology has beaten humans at games of chess and Go to worldwide fanfare. A demonstration of its eerily lifelike prowess in making phone calls to unsuspecting people went viral.But a less-noticed win for DeepMind, the artificial-intelligence arm of Google’s parent Alphabet Inc., at a biennial biology conference could upend how drugmakers find and develop new medicines. It could also dial up pressure on the world’s largest pharmaceutical companies to prepare for a technological arms race. Already, a new breed of upstarts are jumping into the fray.In December, at the CASP13 meeting in Riviera Maya, Mexico, DeepMind beat seasoned biologists at predicting the shapes of proteins, the basic building blocks of disease. The seemingly esoteric pursuit has serious implications: A tool that can accurately model protein structures could speed up the development of new drugs. “Absolutely stunning,” tweeted one scientist after the raw results were posted online. “It was a total surprise,” said conference founder John Moult, a University of Maryland computational biologist. “Compared to the history of what we had been able to do, it was pretty spectacular.” Sorting out the structure of proteins in order to find ways for medicines to attack disease is an enormously complex problem. Researchers still don’t fully understand the rules for how proteins are built. And then there’s the math: There are more possible protein shapes than there are atoms in the universe, making prediction a herculean undertaking of computation. For a quarter century, computational biologists have labored to devise software equal to the task.Enter DeepMind. With limited experience in protein folding — the physical process by which a protein acquires its three-dimensional shape — but armed with the latest neural-network algorithms, DeepMind did more than what 50 top labs from around the world could accomplish. Excitement rippled around the Mayan-themed resort where the meeting was held. Two DeepMind presenters were peppered with questions from scientists about how they had done it. Within hours, the British newspaper The Guardian said DeepMind’s AI could “usher in new era of medical progress.” In a blog post, the company bragged that its protein models were “far more accurate than any that have come before,” opening up “new potential within drug discovery.”In an email, DeepMind said its scientists were “fully focused on their research” and not available for interviews. DeepMind’s simulation doesn’t yet produce the kind of atomic-level resolution that is important for drug discovery. And though many companies are looking for ways to use computers to identify new medications, few machine-learning-based drugs have progressed to the point of being tested in humans. It will be years before anyone knows whether such software can regularly spot promising therapies that researchers might otherwise have missed.Artificial intelligence is a chic catchphrase in health care, often trotted out as a cure-all for whatever ails the industry. It has been held up as a potential solution to fix cumbersome electronic medical records, speed up diagnosis and make surgery more precise. DeepMind’s victory points to a possible practical application for the technology in one of the most expensive and failure-prone parts of the pharmaceutical business. Some observers said that the fact that a team of outsiders could make such significant progress in untangling one of the most vexing problems of biology is a black eye for researchers in the field. It could also be a portent for the drug industry, which spends billions on research and development, but was beaten to the punch. Mohammed AlQuraishi, a Harvard computational biology researcher who attended the conference, wrote in a blog post that giant pharmaceutical companies haven’t put a serious effort into protein folding, essentially ceding the ground to tech companies. While drug companies dithered, “Alphabet swoops in and sets up camp right in their backyard,” he wrote.Finding new drugs and bringing them to market is notoriously difficult. According to some estimates, big drugmakers spend more than $2.5 billion to get a new medicine to patients. Just one of every 10 therapies that enters human clinical trials makes it to the pharmacy. And science moves slowly: In the nearly 20 years since the human genome was sequenced, researchers have found treatments for a tiny fraction of the approximately 7,000 known rare diseases.Further, there are approximately 20,000 genes that can malfunction in at least 100,000 ways, and millions of possible interactions between the resultant proteins. It’s impossible for drug hunters to probe all of those combinations by hand.“If we want to understand the other 97 percent of human biology, we will have to acknowledge it is too complex for humans,” said Chris Gibson, the co-founder and Chief Executive Officer of Recursion Pharmaceuticals, a Salt Lake City-based startup that uses machine learning to hunt for new therapies.Companies like Recursion are rapidly luring investors. Venture capitalists poured $1.08 billion into AI and machine-learning startups focused on drug discovery last year, according to data provider PitchBook, up from just $237 million in 2016, and have already put in $699 million more so far this year. Recursion raised $121 million in its latest financing round, the company said on Monday, from investors including Intermountain Ventures and the Regents of the University of Minnesota. It has a valuation of $646 million, according to PitchBook. “It is a very ambitious company. They are thinking in terms of radically changing the industry,” said Marina Record, an investment manager at Baillie Gifford & Co. in Scotland, which led the funding round.Established drugmakers are racing to ally with companies doing similar work.In April, Gilead Sciences Inc. agreed to a deal with Insitro, a startup led by the former Stanford University machine-learning expert Daphne Koller, to find ways to treat liver disease NASH. AstraZeneca Plc the same month linked up with U.K.-based BenevolentAI to identify treatments for kidney disease and lung fibrosis. In June, GlaxoSmithKline Plc partnered with gene-editing pioneers at the University of California in a $67 million target-hunting collaboration that will use AI.“Where else would you accept a 1-in-10 success rate?” said GlaxoSmithKline senior vice president Tony Wood, who heads medicinal science and technology for the British pharmaceutical giant. “If we could double that to 20% it would be phenomenal.” Machine-learning methods “are going to be critical” to drug discovery, said Juan Alvarez, an associate vice president for computational chemistry at Merck & Co. The giant drugmaker is developing AI tools to help its chemists accelerate the laborious process of crafting chemicals to block aberrant proteins. Early machine-learning efforts have already contributed to drugs in human testing, while the first drugs based on more advanced neural-network methods could hit trials in several years, Alvarez said.Artificial intelligence could be used to scan millions of high-resolution cellular images—more than humans could ever process on their own—to identify therapies that could make diseased cells healthier in unexpected ways.At Recursion, one of the earliest startups to use such methods, each week robots apply thousands of potential drugs to various types of diseased cells, in 400,000 to 500,000 miniature experiments that generate 5 to 10 million cellular images. Machine-learning algorithms then scan the images, searching for compounds that disrupt disease without harming healthy cells. The initial algorithms were coded by hand to interpret basic cellular features, but Recursion is increasingly using neural-network methods that directly interpret the images and may spot patterns human programmers wouldn't have looked for. Computer scientists work in tandem with biologists in the laboratory to refine the leads. The company, which has agreed to rare-disease deals with Takeda Pharmaceutical Co. Ltd. and Sanofi, generated more than 2.5 petabytes of data in the past few years, a total that exceeds roughly the bandwidth of all Hollywood feature films. What the company is doing “just wasn't feasible six, or seven, or eight years ago,” said Gibson, its founder. Gibson first turned to machine learning as a graduate student at the University of Utah searching for treatments for cerebral cavernous malformation, which causes abnormal clumps of leaky blood vessels in the brain. The disorder affects about 1 in 500 people, according to the Angioma Alliance, and while often silent, can lead to seizures, speech or vision difficulties, and devastating brain hemorrhages. About a quarter of patients have a genetic form of the illness that is more likely to cause multiple malformations. Even though the three genes that cause it are known, there are no pharmaceutical treatments. One drug Gibson tested at the University of Utah based on the prevailing understanding of the disease made its symptoms worse in animals.Frustrated, Gibson and his colleagues used open-source machine-learning software for scanning cellular images to probe the effects of 2,100 compounds, searching for ones that improved the appearance and function of blood vessel cells that carried the bad genes. The algorithms pointed to an unexpected chemical that reduced leaky blood vessels in animal tests by 50 percent. That drug, set to enter second-stage human trials next year, led to the founding of Recursion.Other parts of Alphabet, as well as the AI research unit of social-media giant Facebook Inc., which quietly released a paper using deep learning to analyze 250 million protein sequences in April, are creeping into pharmaceutical-company turf. This spring, AI researchers at Google unveiled a neural network that can predict the function of a protein from its sequence of amino acids, which can help biologists understand what a newly discovered protein does. AI proponents say that nobody is talking about taking human researchers out of the equation. The goal is “augmenting and enhancing the decision-making capacity of scientists,” said Jackie Hunter, a former GlaxoSmithKline research executive who now leads clinical programs at BenevolentAI. In the short run, it’s more likely that AI-based simulations will be used to game out whether prospective drugs will be effective before going to a full-on clinical trial.An aerospace company “won’t build and fly a plane without building it on the computer first and simulating it under many conditions,” said Colin Hill of GNS Healthcare, a startup using AI to model disease, whose investors include Amgen Inc. In the future, drugmakers won’t begin clinical trials without a virtual dry run, Hill said.Still, the surprise that unfolded in Mexico has increased the tempo. DeepMind “basically beat everyone by a sizeable margin” said AlQuraishi, the Harvard researcher. If drugmakers don’t take the threat seriously, he said, they could be left in the dust. To contact the author of this story: Robert Langreth in New York at email@example.comTo contact the editor responsible for this story: Drew Armstrong at firstname.lastname@example.org, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
GlaxoSmithKline has announced that a drug acquired in a controversial $5.1bn deal last year has demonstrated its effectiveness in stopping the spread of ovarian cancer when taken as the first treatment after a patient has undergone chemotherapy, in a significant boost for the UK drugmaker. GSK, which has been under pressure to produce new blockbusters amid investor concern that the company was failing to produce as many money-spinning medicines as rivals, said Zejula “met its primary endpoint of a statistically significant improvement in progression free survival for women”, regardless of whether they possessed a particular genetic mutation. The announcement is the company’s most significant oncology data readout since it swapped its cancer drugs business for Novartis’s vaccines division more than five years ago.
GlaxoSmithKline Plc's cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said on Monday. The company bought the drug when it acquired U.S. cancer specialist Tesaro for $5.1 billion in December and Zejula is already approved for certain ovarian cancer patients. For GSK, the success of Zejula would help it access a wider population group and give it an edge over rival PARP inhibitors such as AstraZeneca and Merck & Co's Lynparza and Clovis Oncology's Rubraca.
British digital bank Revolut is nearing the appointment of Martin Gilbert as its new chairman as the bank looks to strengthen its governance. Gilead Sciences will invest $5.1 billion in Galapagos NV to raise its stake in the Belgian biotech group and access its pipeline of drugs under development. GlaxoSmithKline Plc is to hire Jonathan Symonds, the current deputy group chairman of HSBC, as its new chairman to oversee the British drugmaker's break-up.
Symonds' appointment still needs to be finalised and is subject to approval from banking regulators, Bloomberg reported https://bloom.bg/2jSPkal. In January, the company said Chairman Philip Hampton would step down after more than three and a half years in the role. Citing people familiar with the talks, Bloomberg said the appointment could happen in the coming weeks.
GlaxoSmithKline is to hire Jonathan Symonds, a former finance director at rival drugmakers AstraZeneca and Novartis, as its new chairman to oversee a break-up of the UK pharmaceuticals group. The appointment of Mr Symonds, who is currently deputy group chairman of HSBC, will end a six-month search for a replacement for Sir Philip Hampton, who has been non-executive chairman of GSK since 2015. Mr Symonds has extensive experience of the pharmaceutical industry.
(Bloomberg) -- DNA-testing service Vitagene Inc. left thousands of client health reports exposed online for years, the kind of incident that privacy advocates have warned about as gene testing has become increasingly popular.More than 3,000 user files remained accessible to the public on Amazon Web Services cloud-computer servers until July 1, when Vitagene was notified of the issue and shut down external access to the sensitive personal information, according to documents obtained by Bloomberg. The genealogy reports included customers’ full names alongside dates of birth and gene-based health information, such as their likelihood of developing certain medical conditions, a review of the documents showed.Vitagene said that the files dated from when the company was in “beta” testing and represented a small fraction of its customer base.“We immediately opened an investigation and blocked access to the files,” Chief Executive Officer Mehdi Maghsoodnia said in an email. “We updated our security protocols in 2018 and have engaged an outside security firm to run external and internal penetration testing across our application. As a team we acknowledge our mistake and will keep ourselves accountable. We hope over time to prove that we are worthy of the trust that is given to us every day.”Since 2014, closely held Vitagene has helped people craft diet and exercise plans that are molded to their biological traits, lifestyles and goals. The San Francisco-based company generates individualized reports of as many as 60 pages within four- to six-weeks of receiving DNA samples, then walks customers through health-risk factors and recommendations. Vitagene was co-founded by a doctor and a sales executive and says it intends to bring a genetic-based approach to wellness.Advocates say consumers may not understand the data privacy policies of at-home genealogy services. For example, 23andMe Inc. shares anonymized information from its clients with one of its investors, drugmaker GlaxoSmithKline Plc, to help develop new treatments and select patients for clinical trials. The testing company said customers must opt in to each step of the process. Law enforcement agencies have begun tapping DNA companies’ large databases to track down criminals, leading to last year’s capture of the Golden State Killer decades after the crimes. Companies also share DNA data to make a profit.None of those issues has slowed demand for direct-to-consumer genetic-testing kits. The market is expected to reach $2.5 billion of sales a year by 2024, according to Global Market Insights Inc.Vitagene customer records were created from 2015 to 2017. Some of the documents included clients’ contact information, such as some work email addresses, making it easier to confirm people’s identities.The exposure was “extremely significant,” said James Hazel, a postdoctoral fellow at Vanderbilt University’s Center for Genetic Privacy and Identity in Community Settings.“Past breaches have not involved genetic data or test reports,” Hazel said. “This is the first time I’ve heard that genetic data is implicated, which raises a host of privacy issues for the individuals.” Hazel, who has studied the privacy policies of at-home genealogy companies, said this was the type of information malicious actors could have used to try to blackmail individuals or sell to others.Still, for consumers, there can be little recourse in these kinds of data exposures. Companies that make DNA home-testing kits are exempt from U.S. regulations that safeguard patients’ medical records.Vitagene openly stored 4,186 files within one collection on an AWS server, which included thousands of reports on clients. The company left 1,401 user files in a less-secure setting that can typically be accessed by a larger group of its employees than those authorized to view the information.Vitagene emphasized that no credit card data, passwords or other sensitive financial information was exposed. The U.S. Federal Trade Commission in 2014 ruled that DNA testing company GeneLink Inc. must implement new security procedures after alleging the company didn’t safeguard customers’ social security and credit card numbers, amid a broader review of the company’s practices.Vitagene had promised customers that it would protect their identities.“Your results and DNA sample are stored without your name or any other common identifying information,” the company says on its website. “We believe that genetic information deserves the highest level of security. Therefore, your privacy is a top priority at Vitagene.”Vitagene hasn’t yet notified clients about the exposure incident. Customer Julie Chaiken said she first heard that her data was left unsecured when Bloomberg contacted her.“I hope the company is going to reach out to me and let me know how extensive this breach is and how many people have looked at these files,” Chaiken said in an interview. “I hope they get their act together and respect people’s information just like any health-care provider or financial services company we expose our data to.”Vitagene said it would notify affected customers after sifting through all of the leaked files.There were almost 300 files that contained people’s raw genotype DNA data in massive blocks of code accessible to public viewing, but understood only by someone familiar with the science of human genomes. Almost a third of that data was exposed with the user’s first name.Hazel said the presence of that data was very concerning.“Even if raw data is not attached to a name or other personally identifiable information, there’s always a risk with genetic data that a person can be re-identified with that alone,” he said. Many websites allow people to upload genetic data to find relatives, he said.(Updates with context on 23andMe program in the sixth paragraph.)\--With assistance from Josh Eidelson.To contact the reporter on this story: Nico Grant in San Francisco at email@example.comTo contact the editors responsible for this story: Jillian Ward at firstname.lastname@example.org, Andrew Pollack, Alistair BarrFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Dovato, a combination of dolutegravir and lamivudine, was approved in the United States in April for newly-diagnosed patients, boosting the British drugmaker's prospects against Gilead Sciences Inc, which currently leads the HIV treatment market. Liberium analyst Graham Doyle said the study results will add to the data package supporting Dovato as GSK aims to convince doctors that two drug therapies are just as effective as triple therapies. The study evaluated the effectiveness of Dovato in adults with the HIV-1 virus, who switched to the regimen from at least a triple combination containing Gilead's Vemlidy, the British company's HIV drugs division ViiV said.
T-Mobile, Tesla, Marriott, GlaxoSmithKline, Pfizer and Caliva are the companies to watch.
ViiV Healthcare, in which Pfizer Inc. (NYSE: PFE) and SHIONOGI & CO L/ADR (OTC: SGIOY) are also shareholders, announced positive Week 48 results from the Phase 3 TANGO study that evaluated its two-drug regimen in HIV-1 patients. The study assessed whether adult HIV-1 patients who had maintained viral suppression for at least six months on a tenofovir alafenamide fumarate, or TAF-containing three-drug regimen were able to maintain similar rates of viral suppression after switching to the two-drug regimen of dolutegravir plus lamivudine versus the continuation of the TAF regimen.
GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage trial, the drugmaker said on Wednesday. Dovato, a combination of dolutegravir and lamivudine, was approved in the United States in April for newly-diagnosed patients, boosting the British drugmaker's prospects against Gilead Sciences Inc, which currently leads the HIV treatment market. Liberium analyst Graham Doyle said the study results will add to the data package supporting Dovato as GSK aims to convince doctors that two drug therapies are just as effective as triple therapies.
GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage study, the drugmaker said on Wednesday. The study evaluated the effectiveness of Dovato, a combination of dolutegravir and lamivudine, in adults with the HIV-1 virus who switched to the regimen from at least a triple combination containing Gilead Sciences' Vemlidy, the British company's HIV drugs division ViiV said. The positive results further bolster GSK's efforts to challenge U.S. drugmaker Gilead, which currently leads the HIV treatment market.
July 10 (Reuters) - British Drugmaker GlaxoSmithKline Plc on Wednesday said its two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients for 48 weeks at similar levels as the patients' previous three-drug treatment. The company's HIV drugs division ViiV said the late stage study evaluated the effectiveness of Dovato, a combination of dolutegravir and lamivudine, in adults who switched to the regimen from at least a triple combination TAF-containing treatment. Pfizer Inc and Shionogi & Co Ltd have small stakes in ViiV. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard Orr
The United States wants Switzerland to extradite a Chinese researcher accused of helping his scientist sister steal secrets worth $550 million from drugmaker GlaxoSmithKline, Swiss documents released on Monday show. Gongda Xue, who is fighting extradition, has been labeled a potential flight risk, according to a Swiss Federal Criminal Court verdict, keeping him in custody pending the extradition request's resolution. U.S. allegations against Gongda Xue, 49, underscore global fears that China is using networks of highly trained nationals abroad to smuggle trade secrets to the world's second-largest economy.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 2) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) ...
Drug giant GlaxoSmithKline raised the price of cancer drug Zejula by 5 percent this week, bringing the cost for a 30-day supply of 100 milligram Zejula tablets from $6,567 to $6,913.
In the first-quarter earnings investor presentation, GlaxoSmithKline (GSK) reaffirmed adjusted EPS guidance of a YoY decline of 5%–9% YoY in fiscal 2019.
The launch of Mylan’s Wixela Inhub, the generic version of Advair, was a key factor driving down GlaxoSmithKline’s Established Pharmaceuticals revenues.